It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Gonorrhea remains as one of the most common sexually transmitted diseases in developing countries. The third generation cephalosporin such as cefixime is now one of the first-line therapies in many regions. Over the last decade, strains of Neisseria gonorrhoeae have been reported to develop high levels of resistance against several antimicrobial agent cefixime. The purpose of this study is to evaluate the susceptibility of cefixime to Neisseria gonorrhoeae. Methods: The study design was descriptive laboratory observational cross sectional from June 2017 to September 2017. Twenty isolates Neisserria gonorrhoeae taken from outpatients with positive complaints of purulent secretions, who visited 7 Community Health Centre in Surabaya and met the inclusion criterias, were tested with cefixime diffusion susceptibility test. Results: 7 of 20 isolates (35%) were resistant to cefixime and 13 of 20 isolates (65%) sensitive to cefixime. Conclusions: Neisseria gonorhoeae strain was proven to be resistant to cefixime by performing diffusion test.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer